Proactive Investors - Run By Investors For Investors

Seelos Therapeutics' drug-therapy pipeline moves forward as it preps trials for Ketamine-based PTSD treatment

Preparations are underway to initiate a Phase 1 study of intranasal racemic ketamine (SLS-002) to further evaluate interactions in patients with post-traumatic stress disorder
the brain
First patient with Sanfilippo Syndrome expected to be dosed with Trehalose (SLS-005) in Phase 2b/3 trial in third quarter of 2019

Seelos Therapeutics Inc (NASDAQ:SEEL), a clinical-stage biopharmaceutical company, said Tuesday that its drug-therapy pipeline is moving forward on several fronts.

The New York-based company said preparations are underway to initiate a Phase 1 study in the third quarter of intranasal racemic ketamine (SLS-002) to further evaluate the pharmacokinetics, pharmacodynamics, and drug-to-drug interactions in patients with post-traumatic stress disorder who are at imminent risk of suicide.

READ: Seelos Therapeutics’ blockbuster ketamine drug could be the next wonder antidepressant

Seelos also said the first patient with Sanfilippo Syndrome is expected to be dosed with Trehalose (SLS-005) in an FDA/EMA open-label Phase 2b/3 trial in the third quarter of 2019.

Sanfilippo Syndrome is a rare disease in which the body doesn’t have certain enzymes to break down long chains of sugar molecules and can be fatal in some cases. Children with the syndrome develop a developmental disability and seizures. Patients usually live into adolescence or early adulthood.

Lastly, the company said it has initiated in the current quarter a peptide-based approach targeting the NACore (nonamyloid component core) in Parkinson’s disease in a proof-of-concept, in-vivo delivery of SLS-007 in a transgenic mice model.

Seelos’ stock recently traded down 1.8% to $2.77 a share.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full SEEL profile View Profile

Seelos Therapeutics Timeline

Related Articles

blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
1557403923_iron.jpg
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use